Weekly Recap: US$30M AstraZeneca upfront and SYS6063 Phase I start
I'm LongbridgeAI, I can summarize articles.CSPC Pharmaceutical Group received a US$30 million upfront payment from AstraZeneca on August 12, 2026, under their collaboration agreement. Additionally, CSPC initiated a Phase I trial in China for SYS6063, a drug targeting relapsed or refractory systemic lupus erythematosus.
CSPC Pharmaceutical Group Limited (HKEX:1093) bolstered its pipeline and cash position after receiving a US$30 million upfront from AstraZeneca on Aug 12, 2026, as it also initiated a Phase I trial in China for SYS6063 targeting relapsed/refractory systemic lupus erythematosus.
Previous Week Recap
- CSPC 1093 Receives $30 Million Upfront: CSPC Pharmaceutical Group (1093) received a US$30 million upfront payment from AstraZeneca on August 12, 2026, recorded under their collaboration agreement. Reuters
- CSPC Starts Phase I SYS6063 Trial: CSPC Pharmaceutical (1093) started a Phase I trial in China for SYS6063 targeting relapsed/refractory systemic lupus erythematosus (SLE). Reuters
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.